Table 10 Characteristics of patients according to the expression level of POLD1
From: Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Characteristics | High expression (n = 58) | Low expression (n = 35) | P-value |
|---|---|---|---|
Age, years | 52.37 ± 2.385 | 54.98 ± 1.716 | 0.37 |
Male sex | 30 | 18 | 0.98 |
Pre-bevacizumab KPS score | 58.11 ± 1.981 | 59.14 ± 2.669 | 0.75 |
Molecular type | |||
 IDH wild type | 50 | 28 | 0.43 |
 MGMT promoter status (methylated/unmethylated/NA) | 16/5/37 | 17/6/9 |  |
Surgical resection type | |||
 Partial resection | 19 | 18 | 0.07 |
 Gross total resection | 39 | 17 |  |
Drug treatment | |||
 Temozolomide + bevacizumab | 40 | 22 | 0.54 |
 Monotherapy | 18 | 13 |  |
 Temozolomide duration, days | 243.6 ± 29.89 | 209.1 ± 21.91 | 0.41 |
 .Avastin dose, mg/kg | 593 ± 15.84 | 588.3 ± 21.95 | 0.86 |
Treatment outcomes | |||
 Overall survival, days | 878.6 ± 96.25 | 824.4 ± 109.4 | 0.72 |
 Progression-free survival, days | 424.2 ± 61.62 | 471.2 ± 93.68 | 0.66 |
Initial tumor size, mm3 | 44909 ± 5323 | 35735 ± 4914 | 0.24 |
 Recurred tumor size, mm3 | 33590 ± 5377 | 26970 ± 5404 | 0.42 |